Cardiology

The VALIANT study: valsartan to reduce mortalities and cardiovascular morbidities after myocardial infarction

The treatment with valsartan, an angiotensin-receptor blocker, alone or in combination with captopril, an ACE inhibitor, would result in better survival than treatment with a proven ACE-inhibitor regimen. Data come from a randomized, double-blind trial on approximately 14,500 patients comparing the angiotensin-receptor blocker valsartan versus the (ACE) inhibitor captopril.
Read more

 http://www.nejm.org/doi/full/10.1056/NEJMoa032292#t=article...

New England Journal of Medicine